New recommendations regarding the use of DOACs for VTE prevention suggest rivaroxoban or apixaban are among appropriate anticoagulant options regardless of high BMI or weight. Previously, the 2016 guidance from the International Society on Thrombosis and Haemostasis (ISTH) suggested not using DOACs in people with BMI >40 kg/m2 and weight >120 kg. The new recommendations, ...
Guidelines on DOAC use updated for obese patients
By Mardi Chapman
21 Jul 2021